Vivos Therapeutics Revenue 2011-2026 | VVOS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Vivos Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
15 M	13.8 M	16 M	16.9 M	13.1 M	11.4 M	3.79 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
16.9 M	3.79 M	12.9 M

Quarterly Revenue Vivos Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
6.78 M	3.82 M	3.02 M	-	3.86 M	4.05 M	3.42 M	-	3.3 M	3.4 M	3.86 M	-	4.25 M	4.18 M	3.46 M	-	4.55 M	4.5 M	7.74 K	-	21 K	21.7 K	20.9 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.78 M	7.74 K	3.14 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Medical devices industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Acutus Medical AFIB	7.16 M	-	-26.83 %	$ 2.62 M	USA
Allied Healthcare Products AHPI	6.02 M	-	3.58 %	$ 2.21 M	USA
AxoGen AXGN	225 M	$ 28.6	-1.92 %	$ 1.32 B	USA
GenMark Diagnostics, Inc. GNMK	172 M	-	-	$ 1.77 B	USA
Alphatec Holdings ATEC	764 M	$ 12.19	-3.02 %	$ 1.83 B	USA
Axonics Modulation Technologies AXNX	274 M	-	-	$ 3.31 B	USA
Aziyo Biologics AZYO	24.7 M	-	1.37 %	$ 20.5 M	USA
Obalon Therapeutics, Inc. OBLN	1.59 M	-	-5.86 %	$ 30.6 M	USA
Bruker Corporation BRKR	3.37 B	$ 36.62	-4.9 %	$ 5.46 K	USA
Cognyte Software Ltd. CGNT	443 M	$ 8.63	2.92 %	$ 620 M	Israel
Conformis CFMS	62 M	-	-	$ 16.4 M	USA
Cutera CUTR	49.5 M	-	-10.19 %	$ 1.99 M	USA
AdaptHealth Corp. AHCO	3.24 B	$ 9.51	-0.94 %	$ 1.29 B	USA
Electromed ELMD	64 M	$ 24.0	-1.56 %	$ 203 M	USA
Apollo Endosurgery APEN	76.9 M	-	-	$ 475 M	USA
Dynatronics Corporation DYNT	27.4 M	-	14.99 %	$ 929 K	USA
Cardiovascular Systems CSII	236 M	-	0.15 %	$ 844 M	USA
CONMED Corporation CNMD	1.37 B	$ 40.21	-2.9 %	$ 1.25 B	USA
EDAP TMS S.A. EDAP	44.1 M	$ 4.21	-0.94 %	$ 157 M	France
CryoLife, Inc. CRY	253 M	-	-4.14 %	$ 702 M	USA
Avinger AVGR	7.65 M	-	-20.74 %	$ 369 K	USA
Apyx Medical Corporation APYX	52.3 M	$ 3.16	-3.07 %	$ 109 M	USA
Eargo EAR	37.2 M	-	-	$ 10.2 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	4.25 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	41 M	-	0.03 %	$ 1.58 B	Israel
Second Sight Medical Products EYES	1 K	-	-0.97 %	$ 54.4 M	USA
FONAR Corporation FONR	97.6 M	$ 18.48	-0.48 %	$ 121 M	USA
Accuray Incorporated ARAY	459 M	$ 0.49	-2.39 %	$ 50.4 M	USA
Misonix, Inc. MSON	62.5 M	-	-	$ 462 M	USA
Neovasc NVCN	2.55 M	-	-	$ 111 M	Canada
Cytosorbents Corporation CTSO	35.6 M	$ 0.82	1.35 %	$ 44.6 M	USA
Align Technology ALGN	4 B	$ 173.34	-1.29 %	$ 13 B	USA
Intersect ENT, Inc. XENT	80.6 M	-	-	$ 955 M	USA
Butterfly Network BFLY	82.1 M	$ 3.65	-2.93 %	$ 773 M	USA
BIOLASE BIOL	49.2 M	-	-13.19 %	$ 166 K	USA
Abbott Laboratories ABT	44.3 B	$ 109.92	-0.95 %	$ 191 B	USA
IRadimed Corporation IRMD	73.2 M	$ 98.53	-1.57 %	$ 1.25 B	USA
Inogen INGN	349 M	$ 6.46	-1.37 %	$ 172 M	USA
InMode Ltd. INMD	358 M	$ 13.26	-1.45 %	$ 857 M	Israel
BioSig Technologies BSGM	40 K	-	37.08 %	$ 85.7 M	USA
Boston Scientific Corporation BSX	20.1 B	$ 71.46	-2.09 %	$ 106 B	USA
OrthoPediatrics Corp. KIDS	236 M	$ 18.05	1.29 %	$ 423 M	USA
IRIDEX Corporation IRIX	51.9 M	$ 1.24	-10.14 %	$ 20 M	USA
Pulmonx Corporation LUNG	83.8 M	$ 2.03	25.78 %	$ 79.4 M	USA
Helius Medical Technologies HSDT	644 K	$ 2.17	-3.55 %	$ 1.32 M	USA
Medtronic PLC MDT	33.5 B	$ 90.96	-2.2 %	$ 117 B	USA
Edwards Lifesciences Corporation EW	6.07 B	$ 82.03	-2.21 %	$ 48 B	USA